Clinical Trial Update: Inhaled Nitric Oxide and Neuroprotection in Premature Infants [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of inhaled nitric oxide for neuroprotection in premature infants was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Intraventricular Hemorrhage
• Periventricular Leukomalacia
• Prematurity

Drugs mentioned

• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: University of Chicago | Conditions: Prematurity, Bronchopulmonary Dysplasia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-10-17